Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR2 | P30518 | 5/20 | 0.46 |
| ▸ | L3MBTL3 | Q96JM7 | 8/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 8/20 | 0.43 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.43 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
| ▸ | SMYD2 | Q9NRG4 | 1/20 | 0.41 |
| ▸ | MBTD1 | Q05BQ5 | 4/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5785997 | 0.99 | AVPR2 (0.46) | AVPR2L3MBTL3L3MBTL1AVPR1APLA2G7 | |
| SCHEMBL5785737 | 0.92 | AVPR2 (0.46) | AVPR2L3MBTL3L3MBTL1AVPR1ALRRK2 | |
| SCHEMBL5784481 | 0.92 | AVPR2 (0.46) | AVPR2L3MBTL3L3MBTL1AVPR1ALRRK2 | |
| SCHEMBL5784966 | 0.92 | AVPR2 (0.44) | AVPR2L3MBTL3L3MBTL1AVPR1ALRRK2 | |
| SCHEMBL5784041 | 0.92 | AVPR2 (0.47) | AVPR2L3MBTL3L3MBTL1AVPR1ALRRK2 | |
| SCHEMBL5785403 | 0.92 | AVPR2 (0.47) | AVPR2L3MBTL3L3MBTL1AVPR1APLA2G7 | |
| SCHEMBL5784232 | 0.91 | AVPR2 (0.54) | AVPR2L3MBTL3L3MBTL1AVPR1AMBTD1 | |
| SCHEMBL5783747 | 0.91 | AVPR2 (0.44) | AVPR2L3MBTL3L3MBTL1AVPR1ALRRK2 | |
| SCHEMBL5783445 | 0.90 | AVPR2 (0.54) | AVPR2L3MBTL3L3MBTL1AVPR1AMBTD1 | |
| SCHEMBL5782521 | 0.87 | AVPR2 (0.43) | AVPR2L3MBTL3L3MBTL1AVPR1ALRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109193-B2 | Tricyclic diazepines tocolytic oxytocin receptor antagonists | WYETH (US) | 2006-09-19 | — | — | US | claimed |
| EP-1377586-B1 | TRICYCLIC DIAZEPINES AS TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | WYETH CORP (US) | 2006-03-22 | — | — | EP | claimed |
| US-20030008863-A1 | Novel tricyclic diazepines tocolytic oxytocin receptor antagonists | WYETH | 2003-01-09 | — | — | US | claimed |
| US-7109193-B2 | Tricyclic diazepines tocolytic oxytocin receptor antagonists | WYETH (US) | 2006-09-19 | — | — | US | disclosed |
| EP-1377586-B1 | TRICYCLIC DIAZEPINES AS TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | WYETH CORP (US) | 2006-03-22 | — | — | EP | disclosed |
| EP-1377586-A1 | TRICYCLIC DIAZEPINES AS TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | Wyeth (US) | 2004-01-07 | — | — | EP | disclosed |
| US-20030008863-A1 | Novel tricyclic diazepines tocolytic oxytocin receptor antagonists | WYETH | 2003-01-09 | — | — | US | disclosed |
| WO-2002083678-A1 | TRICYCLIC DIAZEPINES AS TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | WYETH (US) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008863-A1 | Novel tricyclic diazepines tocolytic oxytocin receptor antagonists | OXTR, OPRL1, HCRTR2 | AVPR2 91/4885L3MBTL3 3951/4885L3MBTL1 4014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.